glp-1 weight loss drug news november 2025 Who Gets the Shot? Access by State GLP-1 insurance coverage worsened at

The pills havent been compared head-to-head in a clinical trial, but in separate studies, the Wegovy pill showed average weight loss of 14% over 64 weeks, compared with 2% for a placebo, while orforglipron showed 11% weight loss over 72 weeks on its highest dose, compared with 2% for the placebo group

However, careful attention to dosage, baseline Se status, and individual variability is essential to maximize benefits while avoiding toxicity

Thus, preference should be given to molecules with the highest potency, such as semaglutide and dulaglutide, over those with lower potency, like exenatide

Molecular dynamics simulations Atomistic MD simulations were performed starting from the crystal structures of HT with the closed and open form of the TRaQ-G probe, as well as with MeTRaQ-G and TRaQ-G-ctrl probes